Lynne Lanning

Learn More
Membranoproliferative glomerulonephritis type II (MPGN II) is a rare disease characterized by the deposition of abnormal electron-dense material within the glomerular basement membrane of the kidney and often within Bruch's membrane in the eye. The diagnosis is made in most patients between the ages of 5 and 15 yr, and within 10 yr, approximately half(More)
The development of clinical treatment protocols usually relies on evidence-based guidelines that focus on randomized, controlled trials. For rare renal diseases, such stringent requirements can represent a significant challenge. Dense deposit disease (DDD; also known as membranoproliferative glomerulonephritis type II) is a prototypical rare disease. It(More)
Dense deposit disease (DDD) is an ultra-rare renal disease. In the study reported here, 98 patients and their families participated in a descriptive patient-centered survey using an online research format. Reports were completed by patients (38%) or their parents (62%). Age at diagnosis ranged from 1.9 to 38.9 years (mean 14 years). The majority of patients(More)
OBJECTIVE Membranoproliferative Glomerulonephritis (MPGN) is one of a group of glomerulonephritides that often begins in childhood and progresses to renal failure. The purpose of this paper is to describe the initial results of a patient-driven database on individuals with MPGN. SAMPLE/SETTING Patients with MPGN Types I, II, and III and their family(More)
There are three recognized types of Membranoproliferative glomerulonephritis (MPGN). Type II or Dense Deposit Disease (DDD)has a renal survival of 50% at 10 years. The goal of this study was to better identify patients at high risk of early renal failure,and to understand the factors that lead to fast progression of the disease. We identified six diagnostic(More)
  • 1